Eli Lilly’s experimental combination of eloralintide and tirzepatide, nicknamed EloraTZP, helped adults with type 2 diabetes and obesity lose an average of 23.3% of their body weight over 48 weeks, according to a phase 2 trial covered in the reporting behind https://blavity.com/eli-lilly-drug-combo-record-weight-loss-diabetes. That is roughly 54 pounds for an average participant, a result researchers call the strongest weight loss ever recorded in a diabetes drug trial. The combo is not yet approved. It still needs phase 3 testing and FDA review before doctors can prescribe it. This study, highlighting the Eli Lilly Drug Combo Sparks Record Weight Loss in Diabetes Trial, opens up new possibilities for treatment.
What Is the Eli Lilly Drug Combo for Weight Loss and Diabetes
The Eli Lilly Drug Combo Sparks Record Weight Loss in Diabetes Trial, which includes eloralintide and tirzepatide, is revolutionizing how we approach obesity and diabetes management.
The Eli Lilly drug combo making headlines pairs two injectable medications: eloralintide and tirzepatide, together called EloraTZP. It is designed to treat obesity and type 2 diabetes at the same time by attacking appetite and blood sugar through two separate hormone pathways, as detailed in reporting on the record-setting trial results.
Tirzepatide already has FDA approval under two brand names: Mounjaro for diabetes and Zepbound for obesity. Eloralintide is newer and mimics amylin, a hormone the pancreas releases alongside insulin that helps control hunger and slows digestion. Bloomberg’s coverage of the trial confirms Lilly tested the two drugs together, and separately, in a 48-week phase 2 study of 367 adults.
Choose to pay attention to this combo if: you or a family member manages type 2 diabetes alongside stubborn weight gain, since the trial specifically targeted that overlap.
How Does Tirzepatide Work for Weight Loss
Tirzepatide works by activating two gut hormone receptors, GIP and GLP-1, that signal fullness to the brain and slow stomach emptying. This dual action reduces appetite and helps the body use insulin more efficiently, which is why it works for both diabetes and weight management.
GLP-1 alone, the mechanism behind drugs like Ozempic, already slows digestion and curbs hunger. Tirzepatide adds the GIP receptor on top of that, and CNBC’s reporting on the trial notes this dual-hormone approach is part of why tirzepatide already outperforms single-hormone drugs in head-to-head studies. Adding eloralintide’s amylin pathway on top of tirzepatide gives the body a third signal telling the brain to eat less, which is the basis for the new combo’s stronger results.
Common mistake: assuming tirzepatide works the same way as older diabetes drugs like metformin. It does not lower blood sugar through the liver. It works through appetite and digestion, which is why weight loss and blood sugar improvement happen together.
Eli Lilly Weight Loss Drug vs Ozempic: Which Is Better
For weight loss specifically, tirzepatide-based drugs have consistently outperformed semaglutide (Ozempic’s active ingredient) in published comparisons, and the new EloraTZP combo pushes that gap even further. Ozempic targets one hormone pathway; tirzepatide targets two; EloraTZP targets three.
Here is a simple way to compare the options based on current trial data:
Drug or ComboMechanismApprox. Weight LossFDA StatusOzempic (semaglutide)GLP-1 onlyUp to roughly 15% in some trialsFDA approved for diabetes; Wegovy approved for weight lossMounjaro/Zepbound (tirzepatide)GIP/GLP-1 dual~14.8% (15 mg, diabetes trial)FDA approvedEloraTZP (eloralintide + tirzepatide)GIP/GLP-1 plus amylin23.3% (48-week diabetes trial)Experimental, phase 2 onlyRetatrutideTriple hormone (GIP/GLP-1/glucagon)~23% over 80 weeks, diabetes trialStill in late-stage trials
Choose Ozempic if: your doctor is managing mild-to-moderate blood sugar issues and prefers a drug with the longest real-world track record. Choose tirzepatide if: you need stronger weight loss and your doctor confirms you can tolerate dual-hormone side effects. EloraTZP is not yet an option for anyone outside a clinical trial.
How Much Does the Eli Lilly Weight Loss Diabetes Drug Cost
There is no public price for EloraTZP because it is not approved or on the market. Current tirzepatide products, Mounjaro and Zepbound, typically list at over $1,000 per month without insurance, though manufacturer savings cards and insurance coverage can lower that significantly for eligible patients.
Cost remains one of the biggest barriers to these drugs reaching the people who need them most, a concern that echoes broader conversations about why many Americans feel squeezed by rising health and living costs even when new treatments show promise. Insurance coverage for weight loss indications specifically (versus diabetes indications) also varies widely by plan and state.
Edge case: some insurers cover tirzepatide for diabetes but deny it for weight loss alone, even though it is the same drug. Patients often need documentation of a related condition, like high blood pressure or sleep apnea, to get coverage approved.
Is the Eli Lilly Drug Combo Approved by the FDA
No. EloraTZP is not approved by the FDA and remains an experimental, phase 2 treatment. Reuters’ reporting on the trial confirms Lilly has not announced a regulatory submission, and larger phase 3 trials are still required before any approval decision.
Phase 2 trials like this one are designed to test safety and effectiveness in a few hundred people before moving to phase 3, which typically involves thousands of participants over a longer period. That process generally takes several years. Readers should treat the 23.3% weight loss figure as promising early data, not a treatment available today.
Decision rule: if a product, supplement, or online pharmacy claims to sell “EloraTZP” or anything similar right now, that is a red flag. It does not exist as an approved, commercially available drug.
Who Should Take Eli Lilly Tirzepatide for Weight Loss
Tirzepatide, sold as Zepbound for weight loss, is approved for adults with obesity (a BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or sleep apnea. It requires a prescription and medical supervision.
You do not need a diabetes diagnosis to qualify for Zepbound specifically, since it carries its own FDA approval for weight management. Mounjaro, by contrast, is approved specifically for type 2 diabetes. People weighing this decision should talk with their doctor about their full health history, similar to how patients navigate other significant medical choices described in coverage of workers pushing back against pressure around medical decisions.
Tirzepatide is generally not recommended for:
-
People with a personal or family history of medullary thyroid cancer
-
People with Multiple Endocrine Neoplasia syndrome type 2
-
Pregnant or breastfeeding individuals
-
People with a history of severe gastrointestinal disease, without specialist guidance
What Are the Side Effects of the Eli Lilly Weight Loss Drug
The most common side effects of tirzepatide are nausea, diarrhea, vomiting, constipation, and stomach discomfort, especially when starting treatment or increasing the dose. Most side effects are mild to moderate and tend to ease over several weeks as the body adjusts.
In the EloraTZP combo trial, adding eloralintide did not appear to introduce dramatically new safety concerns beyond what is already seen with amylin and GLP-1 drugs, though FierceBiotech’s analysis notes that long-term safety and tolerability still need confirmation in larger phase 3 studies. Rare but serious risks with tirzepatide include pancreatitis, gallbladder problems, and kidney issues tied to dehydration from vomiting or diarrhea.
Anyone managing cardiovascular risk factors alongside a weight loss drug should keep their care team looped in, much like guidance from groups such as the American Heart Association and American Stroke Association recommend for other treatments affecting heart health.
How Much Weight Can You Lose With the Eli Lilly Drug Combo
In the 48-week trial, the highest-dose EloraTZP combo (9 mg eloralintide plus 15 mg tirzepatide) produced an average weight loss of 23.3%, or about 54 pounds, among participants with obesity and type 2 diabetes. That is nearly 8.5 percentage points more than the strongest tirzepatide-only dose, which produced about 14.8% weight loss on its own.
Quartz’s breakdown of the data notes this result also edges past Lilly’s other high-profile obesity candidate, retatrutide, which produced roughly 23% weight loss over a longer 80-week period in a separate diabetes trial. Blood sugar control improved too: A1C dropped by up to 2.9 percentage points in the top-dose combo group, compared with 2.4 points for tirzepatide alone.
Quick example: a 250-pound person in the trial’s top-dose group would, on average, be expected to lose roughly 58 pounds over 48 weeks, based on the 23.3% average reduction reported.
Can You Use Eli Lilly Drug If You Don’t Have Diabetes
Yes, but only through Zepbound, not through EloraTZP. Zepbound is FDA-approved tirzepatide for weight loss in people without diabetes, as long as they meet the BMI and health condition criteria. EloraTZP, the combo drug driving this trial’s headlines, has only been tested in people who already have type 2 diabetes.
It is not yet known whether EloraTZP would produce similar results in people without diabetes, since fat and blood sugar metabolism differ between those groups. Future trials will likely need to test the combo in a broader population before any approval covering non-diabetic patients would be considered.
Eli Lilly Weight Loss Drug vs Mounjaro: What’s the Difference
Mounjaro and Zepbound both contain tirzepatide, the exact same drug, but they are approved for different uses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. EloraTZP is a separate, unapproved combo that adds eloralintide on top of tirzepatide.
Drug NameActive IngredientApproved UseTrial StatusMounjaroTirzepatideType 2 diabetesFDA approvedZepboundTirzepatideChronic weight managementFDA approvedEloraTZPEloralintide + TirzepatideNone yetPhase 2 complete, phase 3 needed
Choose Mounjaro if: your primary concern is diabetes management and your doctor is treating blood sugar first. Choose Zepbound if: weight loss is the primary goal and you meet the BMI criteria. Neither choice gives you EloraTZP, which remains trial-only.
How Long Does It Take to See Results From the Eli Lilly Weight Loss Drug
Most people on tirzepatide-based treatments start noticing appetite changes within the first few weeks, with measurable weight loss typically building over three to six months as the dose increases. In the EloraTZP trial, the full 23.3% average weight loss was measured at the 48-week mark, not immediately.
Weight loss drugs are typically started at a low dose and increased gradually over several weeks to reduce nausea and other digestive side effects. Patients who stop early, before reaching an effective maintenance dose, often see smaller results than the headline trial numbers suggest.
Edge case: people who lose weight quickly in the first month sometimes assume they can stop early. Doctors generally recommend staying on an effective dose long-term, since stopping often leads to regained weight.
Common Mistakes People Make With Tirzepatide Injections
The most common mistakes involve inconsistent dosing schedules, poor injection site rotation, and skipping doses without medical guidance, all of which can blunt the drug’s effectiveness or worsen side effects. Patients should follow their prescriber’s titration schedule closely.
Other frequent errors include:
-
Injecting into the same small area repeatedly, causing irritation or uneven absorption
-
Eating large, high-fat meals right after dosing, which can worsen nausea
-
Not drinking enough water, increasing the risk of dehydration-related kidney strain
-
Expecting results without any changes to diet or activity, despite the drug’s appetite-suppressing effect
-
Stopping suddenly due to side effects instead of talking to a doctor about adjusting the dose
Local support groups and community health resources, like those highlighted through Utica-area disability and health support programming, can help patients stay accountable and informed as they navigate new treatment routines.
Eli Lilly Weight Loss Drug Not Working: Why
If a GLP-1 or tirzepatide-based drug does not seem to be working, the most common reasons are an inadequate dose, inconsistent injection timing, undisclosed dietary habits working against the drug, or an underlying medical issue that needs separate treatment. A doctor can usually identify the cause through bloodwork and a dosing review.
Some patients also have a naturally slower response and need more time at a given dose before an increase makes sense. Yahoo’s coverage of the trial notes that even in controlled trials, individual results varied widely around the reported averages, meaning not everyone hits the 23% mark even on the highest dose.
Decision rule: if weight loss stalls for more than four to six weeks at a stable dose, that is a reasonable trigger to schedule a follow-up with a prescriber rather than assume the drug has failed. Patients juggling multiple prescriptions should also loop in resources like a local Center for Family Life and Recovery if medication management becomes overwhelming.
Frequently Asked Questions
Is EloraTZP the same thing as Zepbound or Mounjaro?
No. EloraTZP is an experimental combination of eloralintide and tirzepatide. Zepbound and Mounjaro both contain only tirzepatide and are already FDA approved.
When will EloraTZP be available to the public?
There is no confirmed timeline. Phase 3 trials and FDA review still need to happen, a process that typically takes several years.
Does the Eli Lilly combo cure type 2 diabetes?
No. It significantly improves blood sugar control and supports major weight loss, but it is a treatment, not a cure. Patients still need ongoing medical management.
How does this compare to Lilly’s retatrutide drug?
Retatrutide produced about 23% weight loss over 80 weeks in a diabetes trial. EloraTZP produced a slightly higher 23.3% in just 48 weeks, making it the faster-acting result so far.
Can I get EloraTZP through my doctor right now?
No. It is only available through clinical trials at this time. Any product claiming to be commercially available EloraTZP should be treated with suspicion.
Is weight regain common after stopping these drugs?
Weight regain is a well-documented risk when GLP-1 or GIP-based drugs are stopped, since the underlying appetite and metabolic effects fade once the medication clears the body.
Does insurance cover tirzepatide for weight loss?
Coverage varies widely. Some plans cover it for diabetes but not weight management, even though it is the same drug under different brand names.
Key Takeaways
-
EloraTZP combines eloralintide (an amylin mimic) with tirzepatide, the active ingredient in Mounjaro and Zepbound.
-
The highest-dose combo produced 23.3% average weight loss, about 54 pounds, in a 48-week trial.
-
Tirzepatide alone, at its highest dose, produced about 14.8% weight loss, or roughly 34 pounds, in the same study.
-
Blood sugar control (A1C) improved more with the combo than with either drug alone.
-
The trial involved 367 adults with obesity or overweight plus type 2 diabetes.
-
EloraTZP is experimental. It has not been submitted for FDA approval.
-
Common side effects mirror other GLP-1 and amylin drugs: nausea, vomiting, and digestive discomfort.
-
People without diabetes may eventually access similar drugs through Zepbound, but EloraTZP itself is not available to anyone yet.
Conclusion
Eli Lilly’s EloraTZP trial marks a genuine step forward in treating two conditions, obesity and type 2 diabetes, that often reinforce each other. The 23.3% average weight loss and improved blood sugar control reported in this 48-week study give doctors and patients real reason for optimism. But reason for optimism is not the same as a treatment ready for your medicine cabinet.
The honest next step for anyone intrigued by this news is a conversation with a primary care provider or endocrinologist about what is actually available today: Mounjaro, Zepbound, or other approved options that fit your health profile and budget. Ask direct questions about dosing, side effects, and insurance coverage before starting anything.
For Mohawk Valley residents weighing these decisions, local clinics and community health resources remain a practical starting point, the same way residents have turned to local programs for vaccine access and other health services in Oneida County. Stay informed, stay skeptical of anything sold outside a doctor’s office, and keep watching for phase 3 results before expecting EloraTZP on pharmacy shelves.
